PTC Therapeutics, Inc. (PTCT) Operating Margin
- Operating margin · 12 months: Value 12.45%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 12.45% | Operating income / revenue. Period ending 2026-06-30. $125.60M ÷ $1.01B × 100 ≈ 12.45% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 125.60M USD | Operating Income (Loss) |
| Revenue | 1.01B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 433.31M USD | Research and Development Expense |
| Selling, general and administration | 347.73M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $125.60M | $1.01B | (m) | $433.31M | $347.73M | 12.45% |
| 2026-03-31 | $-58.33M | $827.11M | (m) | $447.15M | $352.37M | -7.05% |
| 2025-12-31 | $866.93M | $1.73B | (m) | $455.25M | $347.14M | 50.09% |
| 2025-09-30 | $775.89M | $1.78B | (m) | $446.89M | $334.95M | 43.61% |
| 2025-06-30 | $718.37M | $1.76B | (m) | $508.14M | $324.36M | 40.70% |
| 2025-03-31 | $713.11M | $1.77B | (m) | $527.32M | $308.60M | 40.23% |
| 2024-12-31 | $-302.57M | $806.78M | (m) | $534.48M | $300.91M | -37.50% |
| 2024-09-30 | $-134.36M | $900.66M | (m) | $531.06M | $292.52M | -14.92% |
| 2024-06-30 | $-198.01M | $900.45M | (m) | $533.86M | $299.95M | -21.99% |
| 2024-03-31 | $-367.34M | $927.56M | (m) | $587.57M | $318.90M | -39.60% |
| 2023-12-31 | $-439.50M | $937.82M | (m) | $666.56M | $332.54M | -46.86% |
| 2023-09-30 | $-645.66M | $798.18M | (m) | $733.90M | $348.97M | -80.89% |
| 2023-06-30 | $-595.68M | $818.73M | (m) | $735.15M | $348.20M | -72.76% |
| 2023-03-31 | $-478.50M | $770.45M | (m) | $706.54M | $339.64M | -62.11% |
| 2022-12-31 | $-447.41M | $698.80M | (m) | $651.50M | $326.00M | -64.03% |
| 2022-09-30 | $-331.80M | $696.62M | (m) | $612.65M | $319.83M | -47.63% |
| 2022-06-30 | $-356.69M | $618.24M | (m) | $578.03M | $308.96M | -57.69% |
| 2022-03-31 | $-362.82M | $569.39M | (m) | $546.25M | $297.95M | -63.72% |
| 2021-12-31 | $-374.44M | $538.59M | (m) | $540.68M | $285.77M | -69.52% |
| 2021-09-30 | $-386.09M | $492.23M | (m) | $508.85M | $274.68M | -78.44% |
| 2021-06-30 | $-348.14M | $471.89M | (m) | $471.01M | $263.27M | -73.78% |
| 2021-03-31 | $-436.93M | $430.45M | (m) | $522.05M | $248.05M | -101.50% |
| 2020-12-31 | $-431.77M | $380.77M | (m) | $477.64M | $245.16M | -113.39% |
| 2020-09-30 | $-408.18M | (m) | (m) | $441.46M | $233.21M | (m) |
| 2020-06-30 | $-413.52M | (m) | (m) | $411.54M | $224.65M | (m) |
| 2020-03-31 | $-265.01M | (m) | (m) | $294.99M | $220.21M | (m) |
| 2019-12-31 | $-241.16M | (m) | $12.13M | $257.45M | $202.54M | (m) |
| 2019-09-30 | $-213.51M | (m) | (m) | $229.27M | $187.71M | (m) |
| 2019-06-30 | $-201.27M | (m) | (m) | $220.56M | $176.79M | (m) |
| 2019-03-31 | $-168.08M | (m) | (m) | $193.19M | $161.12M | (m) |
| 2018-12-31 | $-115.69M | $264.73M | (m) | $171.98M | $153.55M | -43.70% |
| 2018-09-30 | $-65.10M | (m) | (m) | $147.57M | (m) | (m) |
| 2018-06-30 | $-47.76M | (m) | (m) | $123.23M | (m) | (m) |
| 2018-03-31 | $-54.68M | $223.91M | (m) | $121.46M | (m) | -24.42% |
| 2017-12-31 | $-64.29M | $194.39M | (m) | $117.46M | (m) | -33.07% |
| 2017-09-30 | $-94.73M | $141.55M | (m) | $114.23M | (m) | -66.92% |
| 2017-06-30 | $-95.91M | $122.69M | (m) | $115.61M | (m) | -78.17% |
| 2017-03-31 | $-119.97M | $90.36M | (m) | $113.60M | (m) | -132.77% |
| 2016-12-31 | $-132.06M | $82.70M | (m) | $117.63M | (m) | -159.67% |
| 2016-09-30 | $-155.27M | $70.25M | (m) | $126.67M | (m) | -221.03% |
| 2016-06-30 | $-165.44M | $57.04M | (m) | $125.91M | (m) | -290.04% |
| 2016-03-31 | $-167.50M | $48.18M | (m) | $125.28M | (m) | -347.66% |
| 2015-12-31 | $-167.13M | $36.77M | (m) | $121.82M | (m) | -454.58% |
| 2015-09-30 | $-151.16M | $36.69M | (m) | $113.64M | (m) | -411.99% |
| 2015-06-30 | $-136.53M | $28.61M | (m) | $101.76M | (m) | -477.26% |
| 2015-03-31 | $-123.27M | $23.51M | (m) | $91.89M | (m) | -524.34% |
| 2014-12-31 | $-99.41M | $25.25M | (m) | $79.84M | (m) | -393.79% |
| 2014-09-30 | $-85.28M | $17.00M | (m) | $67.99M | (m) | -501.67% |
| 2014-06-30 | $-61.95M | $31.59M | (m) | $63.11M | (m) | -196.08% |
| 2014-03-31 | $-51.03M | $36.77M | (m) | $59.51M | (m) | -138.79% |
| 2013-12-31 | $-45.40M | $34.70M | (m) | $54.88M | (m) | -130.84% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-29.16M | $28.56M | (m) | (m) | (m) | -102.11% |
| 2012-12-31 | $-26.81M | $33.95M | (m) | $46.14M | (m) | -78.97% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $30.58M | $105.41M | (m) | $58.68M | (m) | 29.01% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |